CGTN: New Approaches : How China pushes COVID-19 vaccine R&D and inoculation
BEIJING, Dec. 20, 2022 /PRNewswire/ — China now has been enhancing its COVID-19 vaccination as a priority especially among the vulnerable
Read MoreBEIJING, Dec. 20, 2022 /PRNewswire/ — China now has been enhancing its COVID-19 vaccination as a priority especially among the vulnerable
Read MoreBEIJING, Dec. 20, 2022 /PRNewswire/ — SARS-CoV-2, the virus causing COVID-19, mutates constantly. Since the beginning of the pandemic three years
Read MoreSAN JOSE, Calif., Dec. 15, 2022 /PRNewswire/ — Published Nov 25, 2022 in the highly respected peer-reviewed journal Phytotherapy Research,
Read MoreBEIJING, Dec. 15, 2022 /PRNewswire/ — Since the outbreak of COVID-19, the world has raced against time, battling the pandemic
Read MoreBEIJING, Dec. 14, 2022 /PRNewswire/ — To echo China’s new guidelines for COVID-19 prevention and control, local governments and hospitals across
Read MoreBEIJING, Dec. 9, 2022 /PRNewswire/ — It’s been nearly three years since China launched the fight against COVID-19. During that
Read MoreThe Novavax BA.1 vaccine candidate met its primary strain-change endpoint allowing for development of variant vaccines, if necessary Novavax’ prototype
Read MoreSINGAPORE, Nov. 1, 2022 /PRNewswire/ — GenScript Biotech Corporation (“GenScript”, Stock Code: 1548.HK), a leading global biotechnology company supported Chulalongkorn
Read MoreGAITHERSBURG, Md., Oct. 19, 2022 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation
Read MoreHomologous boosting with the prototype Novavax COVID-19 vaccine induced robust antibody titers for Omicron BA.1, BA.2, and BA.5 Study 307
Read More